CPORT- E Trial Randomized trial comparing medical, economic and quality of life outcomes of non-primary PCI at hospitals with and without on-site cardiac.

Slides:



Advertisements
Similar presentations
Is this the “spioenkop” for CABG?
Advertisements

Introduction Recent guidelines considered PCI to be a potential alternative to CABG for ULMCA stenosis, based on several large registries and randomized.
Comparison of the New Mayo Clinic Risk Scores and Clinical SYNTAX Score in Predicting Adverse Cardiovascular Outcomes following Percutaneous Coronary Intervention.
Radial versus Femoral Randomized Investigation in ST Elevation Acute Coronary Syndrome the RIFLE STEACS study Enrico Romagnoli, MD PhD Principal investigators:
FFR vs Angiography for Multivessel Evaluation
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs. Everolimus-Eluting Stents for Treatment of Unprotected Left Main Coronary Artery Lesions Julinda Mehilli,
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs. Everolimus-Eluting Stents for Treatment of Unprotected Left Main Coronary Artery Lesions Julinda Mehilli,
2 Year Clinical Outcomes from the Pivotal RESOLUTE US Study Laura Mauri MD, MSc on behalf of the RESOLUTE US Investigators Brigham and Women’s Hospital.
University Medical Center Groningen Thrombus aspiration during primary PCI FZ Thrombus Aspiration during Percutaneous coronary intervention in Acute.
Seung-Jung Park, MD, PhD On behalf of the PRECOMBAT Investigators Professor of Medicine, University of Ulsan College of Medicine, Heart Institute, Asan.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
Francesco Liistro Cardiovascular Department, Arezzo, Italy Impact of Thrombus Aspiration on Myocardial Tissue Reperfusion and Left Ventricular Functional.
Published in Circulation 2005 Percutaneous Coronary Intervention Versus Conservative Therapy in Nonacute Coronary Artery Disease: A Meta-Analysis Demosthenes.
1 1 The Use of Percutaneous Coronary Intervention in Patients with Class I Indications for Coronary Artery Bypass Graft Surgery: Data from the National.
VBWG CHARISMA Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance trial.
Clinical Outcomes with Newer Antihyperglycemic Agents
Proximal Protection during Saphenous Vein Graft Intervention using the Proxis™ Embolic Protection System The PROXIMAL Trial Laura Mauri, MD, MSc, FACC,
CPORT- E Trial Randomized trial comparing outcomes of non-primary PCI at hospitals with and without on-site cardiac surgery.
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.
Ten-Year Follow-up Survival of the Medicine, Angioplasty, or Surgery Study (MASS-II): a Randomized Controlled Clinical Trial of Therapeutic Strategies.
Randomized Trial of Ea rly S urgery Versus Conventional Treatment for Infective E ndocarditis (EASE) Duk-Hyun Kang, MD, PhD on behalf of The EASE Trial.
Impact of Drug-Eluting Stents on Revascularization Choices in Patients with Acute Coronary Syndromes and Multivessel Coronary Disease: Results from the.
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
Bleeding in Patients Undergoing Percutaneous Coronary Interventions: A Risk Model From 302,152 Patients in the NCDR. Sameer K. Mehta MD, Andrew D. Frutkin.
Left Main Trifurcation Disease: Early and Long-Term Outcomes Of Percutaneous Coronary Intervention I.Sheiban, A.Gerasimou, F. Sciuto, P.Omedè, G. Biondi.
Do Tirofiban And ReoPro Give Similar Efficacy Outcomes Trial Presented at AHA Scientific Sessions Nov. 15, 2000.
SIROLIMUS-ELUTING STENTS EFFECTIVELY INHIBIT NEOINTIMAL PROLIFERATION AS COMPARED TO BARE METAL STENTS IN DISEASED SAPHENOUS VEIN GRAFTS: 6-month IVUS.
Endeavor Safety: Pooled Analysis of Early and Late Safety of a Zotarolimus-Eluting Stent Laura Mauri, MD, MSc Brigham and Women’s Hospital Harvard Clinical.
LONG-TERM OUTCOMES OF PERCUTANEOUS CORONARY INTERVENTION FOR UNPROTECTED LEFT MAIN CORONARY ARTERY DISEASE: INITIAL CLINICAL EXPERIENCE. Graidis Ch. 1,
Clinical Trial Results. org Characteristics, Management, and Outcomes of 5,557 Patients Age ≥90 Years With Acute Coronary Syndromes: Results From the CRUSADE.
Clinical Outcomes with Newer Antihyperglycemic Agents FDA-Mandated CV Safety Trials 1.
ADMIRALADMIRAL Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long term follow-up ADMIRAL Study ADMIRAL.
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki.
Allen Jeremias, Neal Kleiman, Deborah Nassif, Wen-Hua Hsieh, Michael Pencina, Kelly Maresh, Manish Parikh, Donald Cutlip, Ron Waksman, Steven Goldberg,
ISAR-CABG Objective To compare the efficacy of DES with BMS in a randomized trial powered for clinical events Sample 610 patients with de novo SVG lesions.
The SAFER Trial Evaluation of the Clinical Safety and Efficacy of the PercuSurge GuardWire in Saphenous Vein Graft Intervention As presented at TCT 2000.
Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Survival of patients with diabetes and multivessel.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Cardioprotective Effects of Postconditioning in Patients Treated with Primary PCI Evaluated with Magnetic Resonance Jacob T Lønborg Niels Vejlstrup, Erik.
RAVEL 4 YEAR FOLLOW-UP - Cordis Cardiology / Cardialysis – Euro-PCR – Sousa – 24 May 2005 RAVEL A RAndomised, double-blind study with the Sirolimus-eluting.
Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Procedural Outcomes of Chronic Total Occlusion Percutaneous.
Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Making Sense of Statistics in Clinical Trial Reports:
1 Do Tirofiban And ReoPro Give Similar Efficacy Outcomes Trial N Engl J Med 2001;344:
Date of download: 9/19/2016 Copyright © The American College of Cardiology. All rights reserved. From: Characteristics and Long-Term Outcomes of Percutaneous.
Durable Polymer DES: 5 Year Outcomes RESOLUTE Update Sigmund Silber, MD FESC, FACC, FAHA Heart Center at the Isar Munich, Germany On Behalf of the RESOLUTE.
Clinical Outcomes with Newer Antihyperglycemic Agents
Clinical Outcomes with Newer Antihyperglycemic Agents
Final Five-Year Follow-up of the SYNTAX Trial: Optimal Revascularization Strategy in Patients With Three-Vessel Disease and/or Left Main Disease Patrick.
Damian Gimpel Waikato Cardiothoracic Unit Journal Club
Vladimir Ganyukov, MD, PhD
Debate: What Does the Future Hold for the Treatment of Unprotected Left Main Disease? More PCI No More Routine Surgery Ron Waksman, MD, FACC Washington.
On behalf of J. Belardi, M. Leon, L. Mauri,
American College of Cardiology Presented by Dr. Stephan Windecker
Giuseppe Biondi Zoccai, MD
3-Year Clinical Outcomes From the RESOLUTE US Study
Comparison of Everolimus- and Biolimus-Eluting Coronary Stents With Everolimus-Eluting Bioresorbable Vascular Scaffolds: 2-year Outcomes of the EVERBIO.
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents: 70 restenotic cases from a cohort of.
(p = 0.32 for noninferiority)
Role of Stenting in Acute MI: PAMI Stent Pilot Trial
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
Maintenance of Long-Term Clinical Benefit with
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
Ahmed A. Khattab, MD For the German Cypher Registry Investigators
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs
Atlantic Cardiovascular Patient Outcomes Research Team
Sirolimus Stent vs. Bare Stent in Acute Myocardial Infarction Trial
NOBLE Trial design: Patients with unprotected left main disease were randomized to either PCI with a drug-eluting stent (DES) (88% biolimus) or CABG. They.
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs
Presentation transcript:

CPORT- E Trial Randomized trial comparing medical, economic and quality of life outcomes of non-primary PCI at hospitals with and without on-site cardiac surgery

Motivation for Trial Sustain primary PCI program at no-SOS hospitals Improve access to PCI services Reduce pressure to create additional cardiac surgery programs Need for research to inform healthcare policy decisions by state and national organizations

C-PORT Elective Patient for Diagnostic Cath Informed consent Catheterization Meets inclusion criteria PCI no SOS PCI with SOS Exclusion criteria Consent Registry Refuse No Consent Registry Not Approached 3:1 Randomization Analysis by intention-to-treat

Study Endpoints Non-inferiority trial Primary Endpoints All-cause mortality at 6 weeks MACE at 9 months All-cause mortality Q-wave myocardial infarction Target vessel revascularization Assuming 6 week mortality to be 0.8%, a sample size of was selected to define a non-inferiority margin of 0.4% with a one-sided test for non-inferiority using α=0.05 and β=0.80 for both primary endpoints.

Inclusion and Exclusion Criteria Patient Institution Inclusion Age > 18 years Informed consent > 50% stenosis All target lesions approachable at no-SOS hospital Exclusion Unprotected LM EF < 20% MD-judged high risk Devices Inclusion Balloon, stent Distal protection Covered stent Cutting balloon - in-stent restenosis Exclusion Atherectomy Cutting balloon- de novo lesion Inclusion > 200 PCI/year 24/7 Primary PCI Complete formal development program Interventionalist meets AHA/ACC competency

Participating Centers 60 Centers Center Annual PCI Procedure Volume 150 (99,216) median (25 th,75 th percentile) Median Participation Duration 2.2 years

99479 Visits Consented No Consent PCI Randomized Not Randomized 2298 PCI Excluded (12%)

18867 PCI Randomized No PCI 299 (1.6%) PCI (98.4% CABG Lesion Not SignificantWithdrawal Medical TxOverall SOS0.73%0.79%0.68%0.51%3.68% No-SOS0.14%0.27%0.12%0.09%0.86% Assigned Unassigned 72 SOS 0.73% No-SOS 0.28% No-SOS SOS 4515

No-SOSSOSp-value Age (years) (mean+/-SD) 64+/ Male Gender (%) Race/Ethnicity (%) Caucasian Africa-American Hispanic 5.6 Asian Hypertension (%) Hypercholesterolemia (%) Smoking (Current & Former) (%) Diabetes (%) Family History of CAD (%) Heart Failure (%) Prior MI (%) Prior PCI (%) Prior CABG (%) Prior Stroke or PVD (%) Creatinine (mg/dl) 1.15+/ / GFR ml/min/1.73 m / / BMI kg/m / /

Presentation Clinical CharacteristicsProcedure Status No-SOS (%) SOS (%) Elective Urgent Emergency No-SOS (%) SOS (%) ACS Stable * P < 0.001

Baseline Diagnostic Catheterization No-SOS (%) SOS (%) p-value One vessel CAD Two vessel CAD Three vessel CAD28.0 Left main disease Graft disease LV function (EF)54.2 +/ / Totals add up to >100% because Left Main and Graft disease are in addition to disease in the three major circulations

Procedure Characteristics No-SOS (%) SOS (%) P- Value Staged < Lab Visits /Index PCI < Single Vessel PCI7978 Multi-Vessel PCI2122 Staged Index PCI procedure requires one or more catheterization laboratory visit dates in addition to the diagnostic catheterization date

PCI Success Patient Success P= Lesion Success P= PCI Success: <20% residual stenosis and TIMI 3 flow

Mortality 6- Weeks No-SOS (%) SOS (%) P-value Death The difference in 6 week mortality is % with a 90% confidence interval of -0.26% to 0.28%. The upper bound is <0.4%, so that the hypothesis of inferior 6 week mortality for the no-SOS hospitals is rejected at the one-sided P<0.05 level.

Adverse Events - 6-Weeks No-SOS (%) SOS (%) P-value Death Bleeding Vascular repair Stroke Renal Failure

Unplanned Procedures No-SOS (%) SOS (%) P-value CABG Emergency CABG Unplanned Cath Unplanned PCI

Summary PCI success is greater than 90% in both groups but lower in patients randomized to hospitals without surgery on-site (success rate difference of 1.1% on per patient basis; 0.7% on per lesion basis) Number of cath lab visits required to complete the index PCI is greater in patients randomized to hospitals with surgery on-site (1.3 versus 1.7 visits/patient) Unplanned catheterization and PCI procedures are uncommon but occur more frequently in patients randomized to hospitals without surgery on-site (4.4% no-SOS vs 3.4% SOS) Emergency CABG procedures are rare, but occur more frequently in patients randomized to hospitals with surgery on-site (0.1% no-SOS vs 0.2% SOS) Mortality is similar in both groups (0.91% no-SOS vs 0.93% SOS) The incidence of bleeding, vascular repair, stroke and renal failure is similar in both groups

Conclusion In hospitals without on-site cardiac surgery that complete a formal PCI development program, adhere to C-PORT participation requirements, and whose outcomes are monitored, non-primary PCI is safe and associated with similar rates of adverse events including mortality. Long-term, quality outcome data are currently being collected on these study subjects and will be reported early in 2012.

Summary Angiographic Outcomes PCI Success > 90% in both groups but lower in hospitals without surgery on-site (success rate difference of 1.1% on per patient basis; 0.7% on per lesion basis) Number of catheterization laboratory visits required to complete the index PCI is greater in patients randomized to hospitals with surgery on-site (1.3 versus 1.7 visits/patient) Unplanned procedure outcomes Unplanned catheterization and PCI procedures were uncommon but occurred more frequently in patients randomized to hospitals without surgery on-site (4.4% no-SOS vs 3.4% SOS) Emergency coronary CABG was rarely required, but was utilized more among patients at hospitals with surgery on-site (0.1% no-SOS vs 0.2% SOS) Patient Outcomes Mortality is similar in both groups (0.91% no-SOS vs 0.93% SOS) The incidence of bleeding, vascular repair, stroke and renal failure is similar in both groups

Summary No SOS (%) SOS (%) Relative Difference Absolute Difference PCI Success %204 Number procedures / index PCI %5570 Unplanned cath or PCI %184 Unplanned emergency CABG %22 Mortality %4 Bleeding %76

Summary - 1 Historical, angiographic and clinical characteristics of study subjects are similar at hospitals with and without on-site surgery Acute coronary syndrome is the most frequent clinical presentation in both groups Fewer procedures are classified as “elective” at hospitals without surgery on-site PCI success rate differs by less than 1% in the two groups, but is statistically lower at hospitals without on-site surgery In patients assigned to hospitals with on-site surgery there are more staged procedures and more catheterization laboratory visits are required to complete the index PCI.

Six weeks after index PCI Mortality is similar at hospitals with and without SOS Incidence of bleeding, renal failure and stroke are similar at hospitals with and without SOS Unplanned CABG, particularly emergency CABG, are more frequent at hospitals with SOS Unplanned catheterization and PCI procedures are more frequent in patient assigned to no-SOS hospitals Summary - 2

Catheterization Laboratory Visits No-SOSSOS Diagnositic Cath Visits Visits to Complete Index PCI Visits/PCI Unplanned Visits Total Visits/PCI

Reason No PCI – consented, not randomized

Consented But Not Randomized PCI at alternate site Exclusion Criteria Need Excluded Device36816% Left Main2189% Poor LV Function1617% High Risk High Risk Anatomy53723% Calcification45220% High Risk (other)41018% Tortuous27012% Co-morbidity2009% Bifurcation1979% Thrombus703% Total > 100 % because of multiple reasons for some patients

PCI Success PCI Success: <50% residual stenosis and TIMI 3 flow * Kutcher MA et al. J Am Coll Cardiol, 2009, 54:16-24

No-SOSSOSOff-Site*On-Site* Age (years) (mean+/-SD) 64+/ Male Gender (%) Race/Ethnicity (%) Caucasian Africa-American Hispanic 5.6 Asian Hypertension (%) Hypercholesterolemia (%) Smoking (Current & Former) (%) Diabetes (%) Family History of CAD (%) Heart Failure (%) Prior MI (%) Prior PCI (%) Prior CABG (%) Prior Stroke or PVD (%) Creatinine (mg/dl) 1.15+/ /-0.87 GFR ml/min/1.73 m / /-27.1 BMI kg/m / /-24.5 * Kutcher MA et al. J Am Coll Cardiol, 2009, 54:16-24

Adverse Events - 6-Weeks No-SOS (%) SOS (%) Off-Site* (%) On-Site* (%) Death Bleeding Vascular repair Stroke Renal Failure * Kutcher MA et al. J Am Coll Cardiol, 2009, 54:16-24

Unplanned Procedures No-SOS (%) SOS (%) Off-Site* (%) On-Site* (%) CABG Emergency CABG Unplanned Cath Unplanned PCI * Kutcher MA et al. J Am Coll Cardiol, 2009, 54:16-24

Disclosure Participating sites supported study infrastructure and personnel at Johns Hopkins – Clinical Coordinating Center Duke – Economics and Quality of Life Clinical Trials and Survey Corporation – Data Analysis